Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 15/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 15/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EEF2K | O00418 | 2/20 | 0.42 |
| ▸ | EEF2 | P13639 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3050549 | 1.00 | CA1 (0.43) | CA1CA2CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL2793948 | 0.98 | CHRM2 (0.43) | CHRM2CHRM1CHRM3HTTEEF2K | |
| Bromide SCHEMBL2797909 | 0.98 | EEF2K (0.43) | CA1CA2CHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL3040164 | 0.95 | CHRM2 (0.41) | CA1CA2CHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL2795641 | 0.95 | CHRM2 (0.41) | CA1CA2CHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL3042366 | 0.95 | CHRM2 (0.41) | CA1CA2CHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL3044853 | 0.95 | CA1 (0.45) | CA1CA2CHRM2CHRM1CHRM3 | |
| SCHEMBL2791768 | 0.95 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HTT | |
| Hydrochloric Acid SCHEMBL2793589 | 0.94 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HTT | |
| Hydrochloric Acid SCHEMBL2793696 | 0.94 | HTT (0.45) | CA1CA2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | CHRM2 1791/4885CHRM1 853/4885CHRM3 1496/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CHRM2 84/4885CHRM1 158/4885CHRM3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.